2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells
Year: 2016
Type: article
Abstract: Tumor cells rely on aerobic glycolysis to generate ATP, namely the "Warburg" effect. 2-deoxyglucose (2-DG) is well characterized as a glycolytic inhibitor, but its effect on cellular signaling pathways has not been fully elucidated. Herein, we sought to investigate the effect of 2-DG on ERK function in lung cancer cells. We found that 2-DG inhibits ERK phosphorylation in a time and dose-dependent manner in lung cancer cells. This inhibition requires functional LKB1. LKB1 knockdown in LKB1 wildtype cells correlated with an increase in the basal level of p-ERK. Restoration of LKB1 in LKB1-null cells significantly inhibits ERK activation. Blocking AMPK function with AMPK inhibitor, AMPK siRNA or DN-AMPK diminishes the inhibitory effect of 2-DG on ERK, suggesting that 2-DG-induced ERK inhibition is mediated by LKB1/AMPK signaling. Moreover, IGF1-induced ERK phosphorylation is significantly decreased by 2-DG. Conversely, a subset of oncogenic mutants of K-Ras, the main upstream regulator of ERK, blocks 2-DG-induced LKB1/AMPK signaling. These findings reveal the potential cross-talk between LKB1/AMPK and ERK signaling and help to better understand the mechanism of action of 2-DG.
Source: PLoS ONE
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: Foundation for the National Institutes of Health, Georgia Cancer Coalition, National Natural Science Foundation of China, China Scholarship Council, Natural Science Foundation of Tianjin City, Tianjin Medical University, National Institutes of Health, Winship Cancer Institute, National Cancer Institute
Awards: G1351369018, Pro-Oncogenic Role of LKB1 in NSCLC, G3735710387, G3810793438, G3982133834, G4622500033, G4926990255, Targeting Cell Signaling in lung cancer to enhance therapeutic efficacy, G6758164892, G682495685, G7196772886, G7475329276, G8022205529, Winship Cancer Institute Cancer Center Support Grant
OpenAlex ID: W2561706117
